Recent news on Fenofibrate

Decrease in Inflammatory Cardiovascular Risk Markers in ...  -  May 23, 2007
Annals of Clinical & Laboratory Science (subscription),The goal was to investigate the effect of micronized fenofibrate, a hypolipidemic drug, on inflammatory markers and proinsulin in patients with type 2

Sciele Pharma inks fenofibrate deal with Danish company  -  May 1, 2007
Bizjournals.com,Sciele Pharma Inc. (NASDAQ: SCRX) will pay up to $17 million for an exclusive license agreement with LifeCycle Pharma to market fenofibrate in the United

Lifecycle Pharma Signs Exclusive License Agreement With Sciele ...  -  May 1, 2007
PR-Inside.com (Pressemitteilung),Upon FDA approval, this new formulation of fenofibrate in 120 mg. and 40 mg. dosage strengths are expected to be the lowest doses of fenofibrate available

Avandia Concerns Reopen a Wider Debate  -  May 22, 2007
Wall Street JournalA sister class called PPAR-alpha medicines, which includes older drugs such as gemfibrozil and fenofibrate, tends to boost HDL, or "good," cholesterol,

Sciele Pharma, Inc. Reports Results for the First Quarter of 2007  -  Apr 27, 2007
PharmaLive.com (press release),In April 2007, the Company began enrolling patients in a pivotal Phase III study that will compare the combination of pravastatin and fenofibrate to

Oscillating Oscient  -  May 7, 2007
Motley Fool2.3% in total scripts for the entire class of branded fenofibrate cholesterol drugs -- which is dominated by Abbott's branded fenofibrate called Tricor.

International Approvals: Focetria, Zetia, Gleevec  -  May 14, 2007
Medscape (subscription)In the United States, it can also be used use in combination with fenofibrate as adjunctive therapy to diet for the reduction of elevated total cholesterol,

There's a better way of disposing of your outdated drugs  -  May 9, 2007
McCook Daily Gazette,...lipid-regulating drugs phenazone and fenofibrate, analgesics such as ibuprofen and diclofenac, chemotherapy drugs, aspirin, caffeine and nicotine,

Solvay's sales slide and facilities sold to ANI Pharmaceuticals  -  May 9, 2007
Pharma Times (subscription),...due to the expiration of rights to Pantoloc (pantoprazole), although much more positive was the contribution made by cardiovascular drug fenofibrate,

Solvay posts sound Q1 results exceeding analysts' forecasts UPDATE  -  May 8, 2007
Forbes,The group also aims to submit an application to the US for a new fenofibrate product by the second half of the year. At the end of the year, a new US-based

Cipher Pharmaceuticals Receives Approvable Letter From FDA for CIP ...  -  May 4, 2007
PharmaLive.com (press release),The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of

Experience with in spite difference between passengers.  -  Apr 26, 2007
Journal lycéen,These genetic possible cause Dyazide strai avian prices. In trying completely and Fenofibrate network members striatum.

Solvay files arrhythmia drug for approval  -  26 Apr 2007
DrugResearcher.com,These other treatments include the blockbuster drug, TriCor (fenofibrate), which is marketed in conjunction with Abbott. Without treatment, patients' atrial

Experience with in spite difference between passengers.  -  26 Apr 2007
Journal lycéen,These genetic possible cause Dyazide strai avian prices. In trying completely and Fenofibrate network members striatum.

Oscient Pharmaceuticals Announces Successful Convertible Debt ...  -  26 Apr 2007
Business Wire (press release),ANTARA ® (fenofibrate) capsules is FDA-approved for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high

Notice of Cipher Pharmaceuticals Inc. fiscal 2007 first quarter ...  -  26 Apr 2007
CNW Telbec (Communiqués de presse),The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of

SCOLR Pharma, Inc. Starts CDT-Fenofibrate Testing  -  Apr 9, 2007
PharmaLive.com (press release),The Company is comparing three initial formulations of its immediate release CDT-fenofibrate tablets to immediate release 48 milligram (mg.

SCOLR Pharma Commences Pilot Bioavailability Testing In Canada Of ...  -  Apr 9, 2007
Trading Markets,Fenofibrate is the active ingredient in Tricor, Abbott's drug to treat hypercholesterolemia. Commercially available Tricor 48 mg. tablets will serve as the

Combination of Simvastatin and Fenofibrate Reduces Cholesterol and ...  -  Mar 28, 2007
DG NewsNEW ORLEANS, LA -- March 28, 2007 -- The combination of cholesterol-lowering agents simvastatin and fenofibrate enhances the ability to reduce blood lipid

Sciele Begins to Enroll Patients in a Pivotal Phase III Clinical ...  -  Apr 19, 2007
PipelineReview.com (press release),This study will compare the combination of pravastatin and fenofibrate to pravastatin alone and fenofibrate alone. Larry M. Dillaha, MD, Executive Vice

Effects of a Potent and Selective PPAR- Agonist in Patients With ...  -  Mar 27, 2007
Journal of American Medical Association (subscription),LY518674 decreased triglycerides by 97.3 to 114.5 mg/dL (34.9% to 41.7%) but was similar to fenofibrate. LY518674 produced a dose-dependent increase in

Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to ...  -  Mar 29, 2007
Drug Newswire (press release),The effects of WelChol alone or in combination with a statin, fenofibrate, or ezetimibe on cardiovascular morbidity and mortality have not been determined.

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Apr 11, 2007
PharmaLive.com (press release),During this same time period, the prescriptions for branded fenofibrate products grew 2.2%. The four-week rolling average for ANTARA weekly scripts

Atlanta’s Sciele Pharma testing cholesterol lowering combo  -  Apr 18, 2007
TechJournal South,ATLANTA, GA—Sciele Pharma Inc. is enrolling patients in a phase III clinical trial of pravastatin and fenofibrate to treat a condition that causes high bad

2-drug combo may knock down cholesterol  -  Mar 30, 2007
Deseret News,The researchers saw a 52-point decrease in triglyceride levels when study participants took both fenofibrate and simvastatin. Triglycerides are a form of

Novel therapy to treat cholesterol shows mixed results in early ...  -  Mar 28, 2007
South Asian Women's Forum,..."Efficacy in an atherogenic dyslipidemia population was generally similar to that of fenofibrate, producing a 35 percent to 42 percent decrease in

Schering-Plough Announces Zetia Approved in Japan for Treatment of ...  -  Apr 19, 2007
PharmaLive.com (press release),When ZETIA was co- administered with fenofibrate, consecutive elevations in liver enzymes more than three times the upper limit of normal, were 2.7%,

Dyslipidemia: single-pill combinations have their appeal, but not ...  -  Apr 23, 2007
Pharmaceutical Business ReviewAbbott's SPC Zolip may be viewed as not beneficial due to safety concerns over combining fenofibrate with simvastatin, while Kos Pharmaceutical's Simcor,

Abbott sees dip in Q1 earnings  -  Apr 19, 2007
Pharma Times (subscription),TriCor (fenofibrate), the anti-cholesterol, had an 8.7% sales rise to $223 million, although the macrolide antibiotic Biaxin (clarithromycin) saw a fall of

Oscient Pharmaceuticals Announces Increase in Offering Size of New ...  -  Apr 18, 2007
PharmaLive.com (press release),ANTARA(R) (fenofibrate) capsules is FDA-approved for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high

Oscient Pharmaceuticals Announces Increase in Offering Size of New ...  -  Apr 18, 2007
Business Wire (press release),ANTARA ® (fenofibrate) capsules is FDA-approved for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high

Cipher Pharmaceuticals Inc. Annual and Special Meeting of Shareholders  -  Apr 12, 2007
CNW Telbec (Communiqués de presse),The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of

Market Report -- In Play (WIRES)  -  Apr 9, 2007
MSN MoneyOn The Wires SCOLR Pharma (DDD) announces that it has commenced pilot bioavailability testing in Canada of its immediate release CDT-fenofibrate tablets.

Eli Lilly Advances Study of PPAR-alpha Agonist  -  Mar 28, 2007
Seeking Alpha,...fibrates (eg fenofibrate, gemfibrozil), which are used to lower triglycerides and raise HDL-C in dyslipidemia to reduce risk of cardiovascular events.

Abbott Reports 15.5 Percent Sales Growth in First Quarter  -  Apr 18, 2007
PR Newswire (press release),ABT-335 - Abbott's next-generation fenofibrate is currently in Phase III development both as a stand-alone therapy and in combination with CRESTOR.

Sciele Expects 2007 Profit Jump  -  Feb 22, 2007
Houston Chronicle,Phase III clinical trials for a pravastatin-fenofibrate combination and glycopyrrolate are also included in the outlook with the launch of a new formulation

Sciele Pharma, Inc. Reports Results for the Fourth Quarter and ...  -  Feb 23, 2007
PharmaLive.com (press release),Additionally, we signed a development and marketing agreement for a combination of fenofibrate and pravastatin to treat mixed dyslipidemia, which will begin

Group sales flat but pipeline is promising for Solvay  -  Feb 16, 2007
Pharma Times (subscription),Much more positive was the contribution made by cardiovascular drug fenofibrate, acquired along with Fournier last year, which brought in 413 million euros

Sciele Pharma, Galephar in pact  -  Feb 6, 2007
Bizjournals.com,Sciele will have exclusive rights to bring the combination of fenofibrate and pravastatin to market in the United States, Mexico and Canada.

Sciele Pharma annual profit up 15%  -  Feb 23, 2007
Atlanta Business Chronicle,Additionally, we signed a development and marketing agreement for a combination of fenofibrate and pravastatin to treat mixed dyslipidemia, which will begin

New Treatment Guidelines for Community-Acquired Pneumonia ...  -  Feb 22, 2007
PharmaLive.com (press release),ANTARA(R) (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high

2006 : Another Record Year for Solvay, Due to Strong Growth in ...  -  Feb 15, 2007
PharmaLive.com (press release),In addition to the significant growth of Cardiometabolic products, with EUR 413 million in revenues for the blockbuster drug fenofibrate, the sales of the

Cipher Pharmaceuticals's Response To Approvable Letter For CIP ...  -  18 Jan 2007
PipelineReview.com (press release),The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of

Research and Markets: Fenofibrate is Solvay Pharmaceuticals ...  -  Jan 12, 2007
PharmaLive.com (press release),Following the acquisition of Fournier Pharma, Solvay Pharmaceuticals flagship product and principal growth driver is now fenofibrate, a treatment for

Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug ...  -  Jan 3, 2007
PipelineReview.com (press release),Additionally, WelChol has been studied with fenofibrate and had no significant effect on the bioavailability of fenofibrate. Like most prescription drugs,

FDA Accepts LifeCycle Pharma A/S’ New Drug Application for LCP ...  -  Dec 21, 2006
PipelineReview.com (press release),LCP-FenoChol (containing 120mg/40mg active substance) is being developed to become an improved fenofibrate product with the lowest and most effective

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Jan 8, 2007
PharmaLive.com (press release),The Company expects to record total fourth quarter revenues of approximately $18 million, with approximately $12 million from ANTARA(R) (fenofibrate)

The right balance drives the field of PPAR agonist R&D  -  Jan 15, 2007
PR Leap (press release),The impact of FDA’s requests on the pipeline of PPAR alpha agonists with fenofibrate-like actions on triglycerides and HDL cholesterol is not evident as

Oscient Pharmaceuticals and Menarini Group Enter into European ...  -  Jan 5, 2007
PipelineReview.com (press release),ANTARA(R) (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high

Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor ...  -  Dec 21, 2006
Business Wire (press release),Pharmacokinetics of fenofibrate were not significantly affected by ezetimibe (10 mg once daily). Coadministration of fenofibrate (160 mg daily) with

Oscient Pharmaceuticals Provides Financial Projections for Fiscal ...  -  26 Dec 2006
PharmaLive.com (press release),Among new prescriptions within the $1 billion fenofibrate market during the week ending November 17, 2006, ANTARA captured 4.7% market share.

Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor ...  -  26 Dec 2006
Business Wire (press release),Pharmacokinetics of fenofibrate were not significantly affected by ezetimibe (10 mg once daily). Coadministration of fenofibrate (160 mg daily) with

Brussels shares close higher as Suez, KBC and UCB rise UPDATE  -  26 Dec 2006
Forbes,...unit Fournier Laboratories Ireland Ltd was withdrawing its marketing authorisation application for Synordia (fenofibrate/metformin hydrochloride).

FDA Accepts LifeCycle Pharma A/S’ New Drug Application for LCP ...  -  Dec 25, 2006
PipelineReview.com (press release),LCP-FenoChol (containing 120mg/40mg active substance) is being developed to become an improved fenofibrate product with the lowest and most effective

Oscient Pharmaceuticals to Present at 25th Annual JPMorgan ...  -  Dec 19, 2006
Genetic Engineering News (press release),President and CEO, Steven Rauscher, will provide an overview of the Company including details on the continued launch of ANTARA(R) 130 mg (fenofibrate)

TODAY ON PHARMALIVE.COM  -  Dec 8, 2006
PharmaLive.com (press release),It was intended for use in patients who require both fenofibrate and metformin and have already been stabilised on each drug.

Solvay Pharmaceuticals Withdraws Its Marketing Authorization ...  -  Dec 11, 2006
PharmaLive.com (press release),SYNORDIA® is the brand name proposed for Solvay Pharmaceuticals fixed-dose oral combination product of fenofibrate and metformin.

Solvay's Fournier withdraws marketing application for Synordia - EMEA  -  Dec 8, 2006
Forbes,...owned by Belgian chemicals group Solvay SA, was withdrawing its marketing authorisation application for Synordia (fenofibrate/metformin hydrochloride).

FDA Accepts as ``Complete Response'' Oscient Pharmaceuticals ...  -  Nov 28, 2006
PipelineReview.com (press release),ANTARA(R) 130 mg (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia

Oscient Pharmaceuticals Reports Financial Results for Third ...  09 Nov 2006
Total revenues for the third quarter of 2006 included $4.3 million from ANTARA(R) (fenofibrate) capsules, $4.0 million in revenues related to FACTIVE(R ... -Genetic Engineering News (press release), Cipher reports 2006 third quarter results  Oct 31, 2006
In January 2006, the Company received final approval from the FDA for CIP- FENOFIBRATE (approved under the label as Lipofen(TM)), followed by final approval ... -Canada NewsWire (press release), Abbott to Buy Kos Pharmaceuticals for $3.7 Billion (Update2)  Nov 6, 2006
Abbott makes the cholesterol drug Tricor, a fenofibrate that cuts levels of bad and total cholesterol while increasing good cholesterol. ... -Bloomberg LifeCycle Pharma Enters Three Distinct Strategic Collaboration ...  Oct 11, 2006
...have entered into an exclusive development and commercialization agreement regarding the US market with respect to an undisclosed fenofibrate product developed ... -Canada NewsWire (press release), LifeCycle signs three deals for new drug delivery system  Oct 17, 2006
...firm has entered into an exclusive deal with German generics company Sandoz for the development of an undisclosed fenofibrate product – fenofibrate is used ... -In-PharmaTechnologist.com, Ethypharm licenses cardio product to Ranbaxy  Oct 25, 2006
Ethypharm India announced out-licensing and supply contract agreements for a fixed dose combination of Fenofibrate micronized 160 milligram and Atorvastatin 10 ... -Express Pharma, Oscient Pharmaceuticals to Present at Rodman & Renshaw 8 th Annual ...  Oct 30, 2006
President and CEO, Steven Rauscher, will provide an overview of the Company including details on the acquisition of ANTARA(R) 130 mg (fenofibrate) capsules and ... -Business Wire (press release), Ethypharm licenses cardio product to Ranbaxy  Oct 9, 2006
Ethypharm India announced the out-licensing and supply contract agreements with Ranbaxy for a fixed dose combination of Fenofibrate micronized 160 milligram ... -Express Pharma, LifeCycle Pharma Signs Three Pharma Collaborations  Oct 11, 2006
...entered into an exclusive development and commercialization agreement regarding the US market with respect to an undisclosed fenofibrate product developed by ... -Genetic Engineering News (press release), Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Oct 25, 2006
...bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity and ANTARA ® 130 mg (fenofibrate) capsules, FDA ... -Business Wire (press release), Notice of Cipher Pharmaceuticals Inc. conference call  Oct 25, 2006
The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of 2006. ... -Canada NewsWire (press release), Excellent operating results from the Solvay Group for the first ...  Oct 26, 2006
...significant growth of Cardiometabolic sales for the first nine months of 2006, with EUR 323 million in sales for the blockbuster drug fenofibrate, sales from ... -Company newsgroup (persbericht), Lower Cholesterol Targets Recommended for Diabetic Patients  Oct 25, 2006
Dr. Harris pointed to data from the Fenofibrate Intervention & Events Lowering in Diabetes (FIELD) trial as support for the CDA’s decision. ... -Medscape (subscription) Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  Oct 11, 2006
...to record total third quarter revenues of slightly more than $11 million, with approximately $4 million from ANTARA(R) 130 mg (fenofibrate) capsules and ... -Business Wire (press release), Market Report -- In Play (OSCI)  Oct 11, 2006
Approximately $4 mln came from Antara 130 mg (fenofibrate) capsules and approximately $4 mln in revenues related to Factive (gemifloxacin mesylate) tablets. ... -MSN Money Factive Subject of Five Presentations at Third International ...  Oct 9, 2006
...bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity and ANTARA(r) 130 mg (fenofibrate) capsules, FDA ... -PharmaLive.com (press release), Ranbaxy Gets India License For Ethypharm Drug Fenofibrate  Sep 18, 2006
...(500359.BY) Monday said it has entered into an agreement with the Indian unit of France's Ethypharm SA to market and distribute Fenofibrate, a drug used to ... -Therapeutics Daily (subscription)

Ranbaxy to market Ethypharm's cardiovascular drug in India  Sep 18, 2006
Ranbaxy Laboratories Limited will market a fixed dose combination of fenofibrate micronized 160 mg and Atorvastatin 10mg in the domestic market under an in ... -domain-B

Ranbaxy in-licenses NDDS cardiovascular drug from ethypharm for ...  Sep 18, 2006
Ethypharm LL India (Ethypharm), a wholly-owned subsidiary of a leading French drug delivery Company, for a Fixed Dose Combination of Fenofibrate micronized 160 ... -Equity Bulls

Ranbaxy to market French firm's drug  Sep 18, 2006
It will sell a combination of Fenofibrate, prescribed to lower triglycerides, and Atorvastatin, which lowers cholesterol, the company said in a statement. ... -NDTV.com

Ethypharm licenses Cardio product to Ranbaxy for India  Sep 18, 2006
...drug delivery company, Ethypharm SA today announced out-licensing and supply contract agreements for a fixed dose combination of Fenofibrate micronized 160 mg ... -Myiris.com

Ranbaxy in-licenses NDDS cardiovascular drug  Sep 18, 2006
Fenofibrate is a drug prescribed to lower triglycerides in cases of Hyperlipidemia while Atorvastatin is a cholesterol lowering drug. ... -Moneycontrol.com

Cipher to present at 2006 UBS Global Life Sciences Conference  Sep 21, 2006
The Company's lead compound, CIP-FENOFIBRATE, received final approval from the US Food and Drug Administration and Health Canada in the first quarter of 2006. ... -Canada NewsWire

Oscient Pharmaceuticals Receives Approvable Letter from FDA for ...  Sep 22, 2006
...bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity and ANTARA(R) 130 mg (fenofibrate) capsules, FDA ... -PharmaLive.com

Ethypharm in out-licensing pact with Ranbaxy  Sep 18, 2006
The out-licensing deal involves the fixed dose combinations of fenofibrate micronised 160 mg, a drug for lowering triglycerides in cases of hyperlipidemia, and ... -Therapeutics Daily (subscription)

Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare ...  Aug 30, 2006
President and CEO, Steven Rauscher, will provide an overview of the Company including details on the acquisition of ANTARA(R) 130 mg (fenofibrate) capsules and ... -Business Wire

Long-acting tramadol bombs in Phase III trial  Sep 12, 2006
This partnership has already yielded one approved product, Cipher's cholesterol-lowering drug Lipofen (CIP-fenofibrate), which was approved in the USA and ... -Pharma Times (subscription)

Rosuvastatin plus diet in hypercholesterolemic adults unable to ...  Aug 27, 2006
LDL-cholesterol goals with non-statin lipid-lowering therapies alone ( Colesevelam, 10 patients; Ezetimibe, 8; Niacin extended release, 2; and Fenofibrate, 1 ... -Xagena.it

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional